awmsg logo



aviptadil phentolamine (Invicorp®)


Reference No. 3435

Publication date:
13/07/2017


Appraisal information

aviptadil phentolamine (Invicorp®) 25 micrograms/2 mg solution for injection


Company: Evolan Pharma AB
BNF category: Obstetrics, gynaecology, and urinary-tract disorders
NMG meeting date: 03/05/2017
AWMSG meeting date: 21/06/2017
   
   
Submission Type: Resubmission
Status: Recommended with restrictions
Advice No: 1117
Ministerial ratification: 12/07/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Aviptadil/phentolamine (Invicorp®) is recommended as an option for the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic, or mixed aetiology. Aviptadil/phentolamine (Invicorp®) is restricted to use in people with erectile dysfunction that has not responded to oral PDE5 inhibitor therapy. Aviptadil/phentolamine (Invicorp®) is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download